Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or RefractoryCD22-expressing B Cell Malignancies

Trial Profile

Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or RefractoryCD22-expressing B Cell Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs JCAR 018 (Primary)
  • Indications Acute lymphoblastic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Nov 2017 Status changed from suspended to recruiting.
    • 02 Nov 2017 Status changed from recruiting to suspended.
    • 01 Nov 2017 According to a Juno Therapeutics media release, results of this trial will be presented at the 59th American Society of Hematology (ASH) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top